Table 2.
Aerosolised Ad5-nCoV group (n=117) | Intramuscular Ad5-nCoV group (n=120) | CoronaVac group (n=119) | p value* | |
---|---|---|---|---|
Adverse reactions within 28 days | ||||
Total (any) | 11 (9%) | 36 (30%) | 17 (14) | <0·0001 |
Grade 3 | 0 | 4 (3%) | 0 | 0·019 |
Solicited administration-site adverse reactions | ||||
Total (any) | 8 (7%) | 27 (23%) | 13 (11%) | 0·0012 |
Redness† (any) | 0 | 3 (3%) | 0 | 0·083 |
Xerostomia (any) | 6 (5%) | 0 | 0 | .. |
Oral ulcer (any) | 1 (1%) | 0 | 0 | .. |
Itch† (any) | 0 | 4 (3%) | 4 (3%) | 0·99 |
Hoarseness (any) | 1 (1%) | 0 | 0 | − |
Pain† (any) | 0 | 26 (22%) | 12 (10%) | 0·014 |
Throat pain (any) | 4 (3%) | 0 | 0 | .. |
Induration† (any) | 0 | 4 (3%) | 2 (2%) | 0·41 |
Swelling† (any) | 0 | 3 (3%) | 0 | 0·083 |
Solicited systemic adverse reactions | ||||
Total (any) | 8 (7%) | 18 (15%) | 6 (5%) | 0·016 |
Nausea (any) | 0 | 2 (2%) | 1 (1%) | 0·37 |
Fever (any) | 1 (1%) | 12 (10%) | 0 | <0·0001 |
Grade 3 | 0 | 4 (3%) | 0 | 0·019 |
Muscle pain (any) | 1 (1%) | 4 (3%) | 0 | 0·075 |
Diarrhoea (any) | 1 (1%) | 3 (3%) | 2 (2%) | 0·62 |
Joint pain (any) | 0 | 3 (3%) | 1 (1%) | 0·18 |
Cough (any) | 4 (3%) | 2 (2%) | 0 | 0·13 |
Runny nose (any) | 3 (3%) | 2 (2%) | 1 (1%) | 0·60 |
Vomiting (any) | 1 (1%) | 1 (1%) | 0 | 0·60 |
Sneeze (any) | 2 (2%) | 1 (1%) | 0 | 0·36 |
Fatigue (any) | 2 (2%) | 8 (7%) | 2 (2%) | 0·049 |
Headache (any) | 3 (3%) | 7 (6%) | 1 (1%) | 0·077 |
Thoracalgia (any) | 1 (1%) | 0 | 0 | 0·36 |
Loss of appetite (any) | 0 | 1 (1%) | 0 | 0·37 |
Throat pain (any) | 0 | 1 (1%) | 0 | 0·37 |
Unsolicited adverse reactions | ||||
Itchy pharynx (any) | 1 (1%) | 0 | 0 | 0·36 |
Data are n (%). Any=all the participants with any grade adverse reactions or events. The analysis was based on the intention-to-treat cohort.
Calculated with χ2 test or Fisher's exact test.
p value shows the result of the comparison between the intramuscular Ad5-nCoV group and the CoronaVac group.